Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.

Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.
复制标题

急性淋巴细胞白血病异柠檬酸脱氢酶突变分析。

DOI:
10.1089/gtmb.2011.0323
复制
发表时间:
2012-08
影响因子:
1.4
通讯作者:
Min Wang
Min Wang
中科院分区:
生物学4区
文献类型:
--
作者:
Jianxiang Wang;HUI WEI;Kejing Tang;Dong Lin;Cuiping Zhang;Yingchang Mi;Lin Wang;Cuicui Wang;Min Wang

文献摘要

参考文献

相似文献

背景 异柠檬酸脱氢酶1/2(IDH 1/2)的精氨酸132位突变是急性髓细胞白血病(AML)的复发性基因改变。随后,这种突变也被发现在各种其他血液恶性肿瘤,包括骨髓增生异常综合征,骨髓增生性疾病,和非霍奇金淋巴瘤。到目前为止,只有少数病例被确定为急性淋巴细胞白血病(ALL)。为研究急性淋巴细胞白血病(ALL)患者IDH的状况,我们分析了54例成人和34例儿童ALL患者的IDH 1/2基因。 结果 确定了3例成人病例和无儿童病例具有异柠檬酸脱氢酶1(IDH 1)突变。在总共88个样本中未发现异柠檬酸脱氢酶2(IDH 2)突变。成人ALL中IDH 1突变的频率为5.5%。在3例IDH 1突变患者中,2例核型正常,并表达髓系标志物。所有三名IDH 1突变患者均在6个月内复发或死亡。 结论 结果表明,IDH 1 R132突变可能是ALL中的一种复发性基因改变;携带该突变的患者有异常表达髓系抗原的趋势,该突变可能意味着令人沮丧的结果。
BACKGROUND Mutations at arginine 132 of isocitrate dehydrogenase 1/2 (IDH1/2) have recently been demonstrated to be recurrent gene alterations in acute myeloid leukemia (AML). Subsequently, this mutation was also found in a variety of other hematologic malignancies, including myelodysplastic syndromes, myeloproliferative diseases, and non-Hodgkin lymphoma. Only a few cases were so far identified in acute lymphoblastic leukemia (ALL). To study the IDH status in ALL patients, we analyzed 54 adult and 34 pediatric ALL samples' IDH1/2 gene. RESULTS Three adult cases and no pediatric case with an isocitrate dehydrogenase 1 (IDH1) mutation were identified. No isocitrate dehydrogenase 2 (IDH2) mutation was identified in the total of 88 samples. The frequency of the IDH1 mutation in adult ALL was 5.5%. Among the three IDH1-mutated patients, two had normal karyotype and expressed the myeloid lineage markers. All three patients with an IDH1 mutation relapsed or died within 6 months. CONCLUSIONS The results suggested that the IDH1 R132 mutation might be a recurrent gene alteration in ALL; patients carrying the mutation have a trend to aberrantly express myeloid antigen and the mutation may imply a dismal outcome.
DOI: 10.1182/blood-2009-03-209262
发表时间: 2009-07-30
期刊: BLOOD
影响因子: 20.3
作者:
Vardiman, James W.;Thiele, Juergen;Bloomfield, Clara D.
通讯作者: Bloomfield, Clara D.
DOI: 10.1016/j.ccr.2010.01.020
发表时间: 2010-03-16
期刊: Cancer cell
影响因子: 50.3
作者:
Ward PS;Patel J;Wise DR;Abdel-Wahab O;Bennett BD;Coller HA;Cross JR;Fantin VR;Hedvat CV;Perl AE;Rabinowitz JD;Carroll M;Su SM;Sharp KA;Levine RL;Thompson CB
通讯作者: Thompson CB
DOI: 10.1097/pai.0b013e31822c132e
发表时间: 2012-01
影响因子: 1.6
作者:
R. Byers;J. Hornick;E. Tholouli;J. Kutok;Scott J. Rodig
通讯作者: R. Byers;J. Hornick;E. Tholouli;J. Kutok;Scott J. Rodig
DOI: 10.1111/j.1365-2141.2010.08423.x
发表时间: 2011-02
影响因子: 6.5
作者:
S. M. Noordermeer;E. Tönnissen;Inge Vissers;A. V. D. van der Heijden;L. T. van de Locht;P. Deutz‐Terlouw;E. Marijt;J. Jansen;B. A. van der Reijden
通讯作者: S. M. Noordermeer;E. Tönnissen;Inge Vissers;A. V. D. van der Heijden;L. T. van de Locht;P. Deutz‐Terlouw;E. Marijt;J. Jansen;B. A. van der Reijden
DOI: 10.1046/j.1460-9568.2002.02055.x
发表时间: 2002-07-01
影响因子: 3.4
作者:
Kölker, S;Pawlak, V;Köhr, G
通讯作者: Köhr, G